Compare YieldMax AI & Tech Portfolio Option Income ETF (GPTY) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AI & Tech Portfolio Option Income ETF vs Medpace Holdings Inc — how do they compare? YieldMax AI & Tech Portfolio Option Income ETF trades at $42.84 (market cap $135.69M), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 124× YieldMax AI & Tech Portfolio Option Income ETF's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, YieldMax AI & Tech Portfolio Option Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax AI & Tech Portfolio Option Income ETF for 61 Days and Medpace Holdings Inc for 14 Days on average.
| GPTY | MEDP | |
|---|---|---|
Market Cap | $135.69M | $16.82B |
Volume | 97,442 | 223,093 |
Sector | Income / Options Overlay | Health |
52-Week High | $50.52 | $630.19 |
52-Week Low | $34.73 | $393.42 |
Typical Hold Time | 61 Days | 14 Days |
Enterprise Value | — | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPTY trades at $42.84, down 0.76% with a bullish technical outlook from moving averages. The ETF maintains consistent weekly dividend distributions averaging $0.29-0.30, providing income generation. Recent coverage highlights the fund's AI-focused covered call strategy as offering high yield potential while retaining some upside participation in tech rallies.
The outlook remains positive for income-seeking investors, with the options-based strategy generating substantial distributions. Key risks include market volatility impacting the underlying AI portfolio and the trade-off between income generation and capital appreciation potential in strong bull markets.
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
